Radiothérapie en conditions stéréotaxiques des métastases cérébrales

F. Dhermain(Institut Gustave Roussy), G. Noël(Hôpital Pierre Wertheimer), F. Mornex(Hôpital Lyon Sud), Philippe Métellus(Centre National de la Recherche Scientifique), Nicolas Reyns(Centre National de la Recherche Scientifique), Philippe Colin(Centre National de la Recherche Scientifique)
Cancer/Radiothérapie
January 29, 2015
10.1016/j.canrad.2014.12.002
Cited by 18

Related Papers

EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
|The Lancet|2017|401
French guidelines on stereoelectroencephalography (SEEG)
|Neurophysiologie Clinique|2017|348
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
|The Lancet Oncology|2021|333